ArticleScientific reports2026

Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment.

Kei Morikawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.